article thumbnail

Regional inequalities threatening Europe’s biosimilars market

European Pharmaceutical Review

With procurement practices across Europe having a strong price focus, over time, this could impact the “sustainability of biosimilars and decrease competition, as well as reducing supply reliability”, the report acknowledged. “As Act4Biosimilars is supported by its founding sponsor, Sandoz.

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

He focuses his practice on EU regulatory affairs, litigation and competition law issues affecting the life sciences sector in Europe. In addition to advising on EU life sciences matters, Maarten also handles competition litigation at the EU and national levels. Maarten has significant competition law experience in a variety of sectors.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Merck defends blockbuster Januvia franchise from patent challenge

pharmaphorum

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug for another few years. billion in the first half of 2022.

article thumbnail

Comparison of Humira biosimilars in the US and Europe

Pharmaceutical Technology

Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. Currently, 40 biosimilars are FDA-approved and 25 have launched, whereas the EMA has approved 86 biosimilars since 2006. The biosimilar market in the US may progress differently this time.

article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The revision process is reviving old conflicts in the pharma industry over fair and affordable access to medicines versus Europe’s status as a competitive home for pharma innovation. EU competitiveness Moll said the legislation revisions should instead be used to make Europe more attractive to pharma companies.

Pharma 64
article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

European regulators have led the way for the development of biosimilars in the past, with 86 approvals granted since 2006″ European regulators have led the way for the development of biosimilars in the past, with 86 approvals granted since 2006. The Impact of Biosimilar Competition in Europe, IQVIA, December 2021.

article thumbnail

Payment delays for pharma MSMEs are a significant problem

eMediWrite

SMEs are also at a disadvantage when compared to their larger counterparts due to delayed payments, which limits their capacity for effective market competition. To ensure prompt payments to MSMEs, strict implementation of current legislation is required, such as the Micro, Small, and Medium Enterprises Development (MSMED) Act, 2006.

Pharma 52